{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T10:49:30Z","timestamp":1791370170601,"version":"4.3.1"},"reference-count":46,"publisher":"American Association for Cancer Research (AACR)","issue":"10","license":[{"start":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T00:00:00Z","timestamp":1791331200000},"content-version":"vor","delay-in-days":6,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,10,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title\/>\n                    <jats:p>The Gustave Roussy Immune (GRIm) score, based on the neutrophil-to-lymphocyte ratio, serum albumin, and lactate dehydrogenase, is a validated prognostic marker in patients receiving immune checkpoint blockers (ICB). We evaluated its prognostic value in patients treated with bispecific CD3 T-cell engagers (TCE) in phase I trials. We retrospectively analyzed prospectively collected data from 150 patients treated with TCEs alone or combined with ICBs across 11 phase I trials at the Drug Development Department, Gustave Roussy (June 2016\u2013February 2025). Overall survival (OS) and progression-free survival (PFS) were estimated using Kaplan\u2013Meier methodology and Cox regression models. Discriminatory performance was assessed using Harrell C-index. Among 150 patients, 127 (85%) had solid tumors, and 23 (15%) had hematologic malignancies; 81% were classified as low-risk GRIm score. Low GRIm score was associated with improved OS [hazard ratio (HR), 0.29; 95% confidence interval (CI), 0.17\u20130.47; P &amp;lt; 0.001; median OS, 17.6 vs. 5 months] and PFS (HR, 0.57; 95% CI, 0.36\u20130.89; P = 0.01; median PFS, 2.8 vs. 1.6 months). In solid tumors, the GRIm score remained prognostic for OS (HR, 0.41; P = 0.002) but not for PFS. In hematologic malignancies, it strongly predicted both OS (HR, 0.04; P &amp;lt; 0.001) and PFS. Multivariable analyses confirmed the GRIm score as independently prognostic for OS (HR, 0.29; P &amp;lt; 0.001) and PFS (HR, 0.60; P = 0.035). Similar findings were observed in patients receiving TCE in monotherapy. The GRIm score independently predicts outcomes in patients receiving TCEs in phase I trials and may support patient selection, particularly in hematologic malignancies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Significance:<\/jats:title>\n                    <jats:p>This study validates the use of the GRIm score as a prognostic tool for patients treated with TCE in early-phase trials. It discriminates between low- and high-risk patients across solid and hematologic malignancies and supports the integration of simple biomarkers into patient selection and risk stratification for bispecific CD3 therapies, improving trial design and remaining feasible in routine clinical practice settings.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1158\/2767-9764.crc-26-0171","type":"journal-article","created":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T09:57:33Z","timestamp":1790157453000},"page":"2339-2349","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Gustave Roussy Immune Score Validation in Patients Treated with Bispecific CD3 T-cell Engagers in Phase I Clinical Trials"],"prefix":"10.1158","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-9788-7471","authenticated-orcid":false,"given":"No\u00e9","family":"Herbel","sequence":"first","affiliation":[{"id":[{"id":"https:\/\/ror.org\/0321g0743","id-type":"ROR","asserted-by":"publisher"}],"name":"Institut Gustave Roussy 1 Drug Development Department, , Villejuif, France."},{"id":[{"id":"https:\/\/ror.org\/0321g0743","id-type":"ROR","asserted-by":"publisher"}],"name":"Institut Gustave Roussy 2 ERC Chromatin Remodeling, DNA Repair and Epigenetics Laboratory, INSERM Unit U981, , Villejuif, France."},{"name":"3Faculty of Medicine, Paris-Sud University XI, Paris-Saclay University, Le Kremlin-Bic\u00eatre, France."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7318-9962","authenticated-orcid":false,"given":"Clara","family":"Helal","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/0321g0743","id-type":"ROR","asserted-by":"publisher"}],"name":"Institut Gustave Roussy 1 Drug Development Department, , Villejuif, France."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8269-3001","authenticated-orcid":false,"given":"Ka\u00efssa","family":"Ouali","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/0321g0743","id-type":"ROR","asserted-by":"publisher"}],"name":"Institut Gustave Roussy 1 Drug Development Department, , Villejuif, France."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1880-064X","authenticated-orcid":false,"given":"Fran\u00e7ois-Xavier","family":"Danlos","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/0321g0743","id-type":"ROR","asserted-by":"publisher"}],"name":"Institut Gustave Roussy 1 Drug Development Department, , Villejuif, France."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2053-8639","authenticated-orcid":false,"given":"Vincent","family":"Goldschmidt","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/0321g0743","id-type":"ROR","asserted-by":"publisher"}],"name":"Institut Gustave Roussy 1 Drug Development Department, , Villejuif, France."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3482-3331","authenticated-orcid":false,"given":"Jean-Marie","family":"Michot","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/0321g0743","id-type":"ROR","asserted-by":"publisher"}],"name":"Institut Gustave Roussy 1 Drug Development Department, , Villejuif, France."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8275-7044","authenticated-orcid":false,"given":"Ariane","family":"Laparra","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/0321g0743","id-type":"ROR","asserted-by":"publisher"}],"name":"Institut Gustave Roussy 4 Department of Medicine, , Villejuif, France."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9902-0877","authenticated-orcid":false,"given":"Arthur","family":"Geraud","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/0321g0743","id-type":"ROR","asserted-by":"publisher"}],"name":"Institut Gustave Roussy 1 Drug Development Department, , Villejuif, France."},{"id":[{"id":"https:\/\/ror.org\/035xkbk20","id-type":"ROR","asserted-by":"publisher"}],"name":"Aix-Marseille Universit\u00e9 5 Department of Medical Oncology, CRCM, CNRS, INSERM, Institut Paoli-Calmettes, , Marseille, France."},{"id":[{"id":"https:\/\/ror.org\/035xkbk20","id-type":"ROR","asserted-by":"publisher"}],"name":"Aix-Marseille University 6 COMPO Team, Centre de Recherche en Canc\u00e9rologie de Marseille (CRCM), Inserm U1068, , Marseille, France."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3923-5160","authenticated-orcid":false,"given":"Patricia","family":"Martin-Romano","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/0321g0743","id-type":"ROR","asserted-by":"publisher"}],"name":"Institut Gustave Roussy 1 Drug Development Department, , Villejuif, France."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0995-5378","authenticated-orcid":false,"given":"P\u00e9rine","family":"Vuagnat","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/0321g0743","id-type":"ROR","asserted-by":"publisher"}],"name":"Institut Gustave Roussy 1 Drug Development Department, , Villejuif, France."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9706-3945","authenticated-orcid":false,"given":"Alice","family":"Bernard-Tessier","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/0321g0743","id-type":"ROR","asserted-by":"publisher"}],"name":"Institut Gustave Roussy 4 Department of Medicine, , Villejuif, France."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6866-6787","authenticated-orcid":false,"given":"Anas","family":"Gazzah","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/0321g0743","id-type":"ROR","asserted-by":"publisher"}],"name":"Institut Gustave Roussy 1 Drug Development Department, , Villejuif, France."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-8257-6053","authenticated-orcid":false,"given":"Rastislav","family":"Bahleda","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/0321g0743","id-type":"ROR","asserted-by":"publisher"}],"name":"Institut Gustave Roussy 1 Drug Development Department, , Villejuif, France."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2869-7551","authenticated-orcid":false,"given":"Antoine","family":"Hollebecque","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/0321g0743","id-type":"ROR","asserted-by":"publisher"}],"name":"Institut Gustave Roussy 1 Drug Development Department, , Villejuif, France."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-3898-408X","authenticated-orcid":false,"given":"Linda","family":"Mahjoubi","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/0321g0743","id-type":"ROR","asserted-by":"publisher"}],"name":"Institut Gustave Roussy 1 Drug Development Department, , Villejuif, France."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7893-3116","authenticated-orcid":false,"given":"Cl\u00e9mence","family":"Henon","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/0321g0743","id-type":"ROR","asserted-by":"publisher"}],"name":"Institut Gustave Roussy 1 Drug Development Department, , Villejuif, France."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5562-1857","authenticated-orcid":false,"given":"Sophie","family":"Postel-Vinay","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/0321g0743","id-type":"ROR","asserted-by":"publisher"}],"name":"Institut Gustave Roussy 1 Drug Development Department, , Villejuif, France."},{"id":[{"id":"https:\/\/ror.org\/0321g0743","id-type":"ROR","asserted-by":"publisher"}],"name":"Institut Gustave Roussy 2 ERC Chromatin Remodeling, DNA Repair and Epigenetics Laboratory, INSERM Unit U981, , Villejuif, France."},{"name":"3Faculty of Medicine, Paris-Sud University XI, Paris-Saclay University, Le Kremlin-Bic\u00eatre, France."},{"name":"7University College of London Cancer Institute, London, United Kingdom."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8338-1739","authenticated-orcid":false,"given":"Yohann","family":"Loriot","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/0321g0743","id-type":"ROR","asserted-by":"publisher"}],"name":"Institut Gustave Roussy 1 Drug Development Department, , Villejuif, France."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5221-353X","authenticated-orcid":false,"given":"Vincent","family":"Ribrag","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/0321g0743","id-type":"ROR","asserted-by":"publisher"}],"name":"Institut Gustave Roussy 1 Drug Development Department, , Villejuif, France."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6068-9474","authenticated-orcid":false,"given":"Karim","family":"Fizazi","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/0321g0743","id-type":"ROR","asserted-by":"publisher"}],"name":"Institut Gustave Roussy 4 Department of Medicine, , Villejuif, France."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2289-4709","authenticated-orcid":false,"given":"Santiago","family":"Ponce-Aix","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/0321g0743","id-type":"ROR","asserted-by":"publisher"}],"name":"Institut Gustave Roussy 1 Drug Development Department, , Villejuif, France."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5816-3019","authenticated-orcid":false,"given":"Aur\u00e9lien","family":"Marabelle","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/0321g0743","id-type":"ROR","asserted-by":"publisher"}],"name":"Institut Gustave Roussy 1 Drug Development Department, , Villejuif, France."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5505-0564","authenticated-orcid":false,"given":"Christophe","family":"Massard","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/0321g0743","id-type":"ROR","asserted-by":"publisher"}],"name":"Institut Gustave Roussy 1 Drug Development Department, , Villejuif, France."},{"name":"3Faculty of Medicine, Paris-Sud University XI, Paris-Saclay University, Le Kremlin-Bic\u00eatre, France."},{"name":"8Molecular Radiotherapy Unit 1030, National Institute of Health and Medical Research (INSERM), Paris, France."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0741-2118","authenticated-orcid":false,"given":"St\u00e9phane","family":"Champiat","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/0321g0743","id-type":"ROR","asserted-by":"publisher"}],"name":"Institut Gustave Roussy 1 Drug Development Department, , Villejuif, France."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0604-7614","authenticated-orcid":false,"given":"Capucine","family":"Baldini","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/0321g0743","id-type":"ROR","asserted-by":"publisher"}],"name":"Institut Gustave Roussy 1 Drug Development Department, , Villejuif, France."},{"id":[{"id":"https:\/\/ror.org\/0321g0743","id-type":"ROR","asserted-by":"publisher"}],"name":"Institut Gustave Roussy 9 Laboratory of Immunomonitoring in Oncology, , Villejuif, France."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1086","published-online":{"date-parts":[[2026,10,7]]},"reference":[{"key":"2026100705504563600_bib1","doi-asserted-by":"publisher","first-page":"5663","DOI":"10.1158\/1078-0432.ccr-14-0719","article-title":"Dose\u2013response relationship in phase I clinical trials: a European Drug Development Network (EDDN) Collaboration Study","volume":"20","author":"Moreno Garc\u00eda","year":"2014","journal-title":"Clin Cancer Res"},{"key":"2026100705504563600_bib2","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1023\/a:1008368319526","article-title":"Multivariable analysis of prognostic factors for toxicity and survival for patients enrolled in phase I clinical trials","volume":"11","author":"Bachelot","year":"2000","journal-title":"Ann Oncol"},{"key":"2026100705504563600_bib3","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.annonc.2022.09.158","article-title":"Oncology phase I trial design and conduct: time for a change - MDICT Guidelines 2022","volume":"34","author":"Araujo","year":"2023","journal-title":"Ann Oncol"},{"key":"2026100705504563600_bib4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ejca.2023.04.006","article-title":"Profile and outcome of cancer patients enrolled in contemporary phase I trials","volume":"188","author":"Alouani","year":"2023","journal-title":"Eur J Cancer"},{"key":"2026100705504563600_bib5","doi-asserted-by":"publisher","first-page":"2242","DOI":"10.1056\/nejmc1803837","article-title":"Encouraging trends in modern phase 1 oncology trials","volume":"378","author":"Chakiba","year":"2018","journal-title":"N Engl J Med"},{"key":"2026100705504563600_bib6","doi-asserted-by":"publisher","first-page":"103860","DOI":"10.1016\/j.critrevonc.2022.103860","article-title":"A systematic review of contemporary phase I trials in patients with lymphoma","volume":"180","author":"Griguolo","year":"2022","journal-title":"Crit Rev Oncol Hematol"},{"key":"2026100705504563600_bib7","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1038\/s41571-019-0262-9","article-title":"Phase I trials as valid therapeutic options for patients with cancer","volume":"16","author":"Adashek","year":"2019","journal-title":"Nat Rev Clin Oncol"},{"key":"2026100705504563600_bib8","doi-asserted-by":"publisher","first-page":"5666","DOI":"10.1158\/1078-0432.ccr-16-0663","article-title":"FDA approval summary: accelerated approval of pembrolizumab for second-line treatment of metastatic melanoma","volume":"23","author":"Chuk","year":"2017","journal-title":"Clin Cancer Res"},{"key":"2026100705504563600_bib9","doi-asserted-by":"publisher","first-page":"1388","DOI":"10.1093\/annonc\/mdx076","article-title":"Pembrolizumab KEYNOTE-001: an adaptive study leading to accelerated approval for two indications and a companion diagnostic","volume":"28","author":"Kang","year":"2017","journal-title":"Ann Oncol"},{"key":"2026100705504563600_bib10","doi-asserted-by":"publisher","first-page":"2692","DOI":"10.1200\/jco.2008.19.5081","article-title":"Prospective validation of a prognostic score to improve patient selection for oncology phase I trials","volume":"27","author":"Arkenau","year":"2009","journal-title":"J Clin Oncol"},{"key":"2026100705504563600_bib11","doi-asserted-by":"publisher","first-page":"e1068494","DOI":"10.1080\/2162402x.2015.1068494","article-title":"Prime time for immune-checkpoint targeted therapy at ASCO 2015","volume":"5","author":"Marabelle","year":"2016","journal-title":"Oncoimmunology"},{"key":"2026100705504563600_bib12","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1016\/j.ejca.2017.07.027","article-title":"Prospective validation of a prognostic score for patients in immunotherapy phase I trials: the Gustave Roussy Immune Score (GRIm score)","volume":"84","author":"Bigot","year":"2017","journal-title":"Eur J Cancer"},{"key":"2026100705504563600_bib13","doi-asserted-by":"publisher","first-page":"163","DOI":"10.6004\/jadpro.2023.14.2.7","article-title":"Teclistamab-cqyv: the first bispecific T-cell engager antibody for the treatment of patients with relapsed or refractory multiple myeloma","volume":"14","author":"Hua","year":"2023","journal-title":"J Adv Pract Oncol"},{"key":"2026100705504563600_bib14","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1093\/annonc\/mdz115","article-title":"T-cell bispecific antibodies to bypass MHC class I loss in breast cancer","volume":"30","author":"Marra","year":"2019","journal-title":"Ann Oncol"},{"key":"2026100705504563600_bib15","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1016\/j.ymeth.2018.10.026","article-title":"Bispecific T-cell engagers: towards understanding variables influencing the in vitro potency and tumor selectivity and their modulation to enhance their efficacy and safety","volume":"154","author":"Ellerman","year":"2019","journal-title":"Methods"},{"key":"2026100705504563600_bib16","doi-asserted-by":"publisher","first-page":"1470595","DOI":"10.3389\/fphar.2024.1470595","article-title":"T-cell engagers: model interrogation as a tool to quantify the interplay of relative affinity and target expression on trimer formation","volume":"15","author":"Lai","year":"2024","journal-title":"Front Pharmacol"},{"key":"2026100705504563600_bib17","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1016\/j.ccell.2023.02.008","article-title":"The pre-existing T-cell landscape determines the response to bispecific T-cell engagers in multiple myeloma patients","volume":"41","author":"Friedrich","year":"2023","journal-title":"Cancer Cell"},{"key":"2026100705504563600_bib18","doi-asserted-by":"publisher","first-page":"2364","DOI":"10.1038\/s41591-022-02015-7","article-title":"Clinical and molecular response to tebentafusp in previously treated patients with metastatic uveal melanoma: a phase 2 trial","volume":"28","author":"Carvajal","year":"2022","journal-title":"Nat Med"},{"key":"2026100705504563600_bib19","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1038\/s41571-024-00905-y","article-title":"Bispecific and multispecific antibodies in oncology: opportunities and challenges","volume":"21","author":"Goebeler","year":"2024","journal-title":"Nat Rev Clin Oncol"},{"key":"2026100705504563600_bib20","doi-asserted-by":"publisher","first-page":"6226","DOI":"10.1182\/blood-2012-01-400515","article-title":"Immunopharmacologic response of patients with B-lineage acute lymphoblastic leukemia to continuous infusion of T-cell-engaging CD19\/CD3-bispecific BiTE antibody blinatumomab","volume":"119","author":"Klinger","year":"2012","journal-title":"Blood"},{"key":"2026100705504563600_bib21","doi-asserted-by":"publisher","first-page":"e143","DOI":"10.1016\/s1470-2045(17)30074-8","article-title":"iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics","volume":"18","author":"Seymour","year":"2017","journal-title":"Lancet Oncol"},{"key":"2026100705504563600_bib22","doi-asserted-by":"publisher","first-page":"2893","DOI":"10.1200\/jco.22.02823","article-title":"Tarlatamab, a first-in-class DLL3-targeted bispecific T-cell engager, in recurrent small-cell lung cancer: an open-label, phase I study","volume":"41","author":"Paz-Ares","year":"2023","journal-title":"J Clin Oncol"},{"key":"2026100705504563600_bib23","doi-asserted-by":"publisher","first-page":"274","DOI":"10.4103\/0974-7788.76794","article-title":"Understanding survival analysis: Kaplan\u2013Meier estimate","volume":"1","author":"Kishore","year":"2010","journal-title":"Int J Ayurveda Res"},{"key":"2026100705504563600_bib24","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1002\/(sici)1097-0258(19960229)15:4&lt;361::aid-sim168&gt;3.0.co;2-4","article-title":"Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors","volume":"15","author":"Harrell","year":"1996","journal-title":"Statist Med"},{"key":"2026100705504563600_bib25","doi-asserted-by":"publisher","first-page":"3160","DOI":"10.1002\/sim.4058","article-title":"An application of Harrell\u2019s C-index to PH frailty models","volume":"29","author":"Van Oirbeek","year":"2010","journal-title":"Statist Med"},{"key":"2026100705504563600_bib26","doi-asserted-by":"publisher","first-page":"dju124","DOI":"10.1093\/jnci\/dju124","article-title":"Prognostic role of neutrophil-to-lymphocyte ratio in solid tumors: a systematic review and meta-analysis","volume":"106","author":"Templeton","year":"2014","journal-title":"J Natl Cancer Inst"},{"key":"2026100705504563600_bib27","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1186\/s12916-020-01817-1","article-title":"Neutrophil to lymphocyte ratio and cancer prognosis: an umbrella review of systematic reviews and meta-analyses of observational studies","volume":"18","author":"Cupp","year":"2020","journal-title":"BMC Med"},{"key":"2026100705504563600_bib28","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1159\/000092969","article-title":"The inflammatory tumor microenvironment and its impact on cancer development","volume-title":"Contributions to microbiology","author":"de Visser","year":"2006"},{"key":"2026100705504563600_bib29","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1186\/1475-2891-9-69","article-title":"Pretreatment serum albumin as a predictor of cancer survival: a systematic review of the epidemiological literature","volume":"9","author":"Gupta","year":"2010","journal-title":"Nutr J"},{"key":"2026100705504563600_bib30","doi-asserted-by":"publisher","first-page":"1612","DOI":"10.1093\/annonc\/mdx172","article-title":"Clinical validation of a prognostic tool in a population of outpatients treated for incurable cancer undergoing anticancer therapy: PRONOPALL study","volume":"28","author":"Bourgeois","year":"2017","journal-title":"Ann Oncol"},{"key":"2026100705504563600_bib31","doi-asserted-by":"publisher","first-page":"S915","DOI":"10.1016\/j.annonc.2020.08.1965","article-title":"1459P Albumin as a simple criterion to reduce early mortality (EM) in gastric cancer (GC) trials","volume":"31","author":"Ozguroglu","year":"2020","journal-title":"Ann Oncol"},{"key":"2026100705504563600_bib32","doi-asserted-by":"publisher","first-page":"e1002202","DOI":"10.1371\/journal.pbio.1002202","article-title":"Lactate regulates metabolic and pro-inflammatory circuits in control of T-cell migration and effector functions","volume":"13","author":"Haas","year":"2015","journal-title":"PLoS Biol"},{"key":"2026100705504563600_bib33","doi-asserted-by":"publisher","first-page":"961","DOI":"10.3109\/0284186x.2015.1043026","article-title":"Prognostic role of lactate dehydrogenase in solid tumors: a systematic review and meta-analysis of 76 studies","volume":"54","author":"Petrelli","year":"2015","journal-title":"Acta Oncol"},{"key":"2026100705504563600_bib34","doi-asserted-by":"publisher","first-page":"1916","DOI":"10.1038\/s41416-023-02214-0","article-title":"Systemic inflammatory prognostic scores in advanced pancreatic adenocarcinoma","volume":"128","author":"Ma","year":"2023","journal-title":"Br J Cancer"},{"key":"2026100705504563600_bib35","doi-asserted-by":"publisher","first-page":"98","DOI":"10.14740\/wjon1275","article-title":"Gustave Roussy immune score and Royal Marsden Hospital prognostic score are prognostic markers for extensive disease of small cell lung cancer","volume":"11","author":"Minami","year":"2020","journal-title":"World J Oncol"},{"key":"2026100705504563600_bib36","doi-asserted-by":"publisher","first-page":"e58935","DOI":"10.7759\/cureus.58935","article-title":"Gustave Roussy Immune Score (GRIm score) as a prognostic and predictive score in metastatic colorectal cancer","volume":"16","author":"Cotan","year":"2024","journal-title":"Cureus"},{"key":"2026100705504563600_bib37","doi-asserted-by":"publisher","first-page":"2640","DOI":"10.7150\/ijms.99724","article-title":"The Gustave Roussy Immune score (GRIm score) as a novel prognostic score for early breast cancer patients: a real-world retrospective study","volume":"21","author":"Tan","year":"2024","journal-title":"Int J Med Sci"},{"key":"2026100705504563600_bib38","doi-asserted-by":"publisher","first-page":"1302","DOI":"10.1007\/s10147-024-02563-7","article-title":"Gustave Roussy Immune score as a prognostic biomarker in patients with platinum-refractory metastatic urothelial carcinoma treated with pembrolizumab: YUSHIMA study","volume":"29","author":"Tanabe","year":"2024","journal-title":"Int J Clin Oncol"},{"key":"2026100705504563600_bib39","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1080\/01635581.2024.2361508","article-title":"Prognostic value of the Gustave Roussy Immune score in lung cancer: a meta-analysis","volume":"76","author":"Ji","year":"2024","journal-title":"Nutr Cancer"},{"key":"2026100705504563600_bib40","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1186\/s12885-024-12149-1","article-title":"Association of the Advanced Lung Cancer Inflammation Index (ALI) and Gustave Roussy Immune (GRIm) score with immune checkpoint inhibitor efficacy in patients with gastrointestinal and lung cancer","volume":"24","author":"Jiang","year":"2024","journal-title":"BMC Cancer"},{"key":"2026100705504563600_bib41","doi-asserted-by":"publisher","first-page":"2236640","DOI":"10.1080\/07853890.2023.2236640","article-title":"Prognostic significance of the Gustave Roussy immune (GRIm) score in cancer patients: a meta-analysis","volume":"55","author":"Sun","year":"2023","journal-title":"Ann Med"},{"key":"2026100705504563600_bib42","doi-asserted-by":"publisher","first-page":"7400","DOI":"10.1245\/s10434-022-12226-4","article-title":"Changes in the Gustave Roussy Immune score as a powerful prognostic marker of the therapeutic sensitivity of nivolumab in advanced gastric cancer: a multicenter, retrospective study","volume":"29","author":"Nakazawa","year":"2022","journal-title":"Ann Surg Oncol"},{"key":"2026100705504563600_bib43","doi-asserted-by":"publisher","first-page":"e33334","DOI":"10.1097\/md.0000000000033334","article-title":"Prognostic value of modified-Gustave-Roussy Immunity Score in resectable proximal gastric cancer","volume":"102","author":"Shi","year":"2023","journal-title":"Medicine"},{"key":"2026100705504563600_bib44","doi-asserted-by":"publisher","first-page":"4259","DOI":"10.1002\/cam4.5294","article-title":"The hepatocellular carcinoma modified Gustave Roussy Immune score (HCC-GRIm score ) as a novel prognostic score for patients treated with atezolizumab and bevacizumab: a multicenter retrospective analysis","volume":"12","author":"Hatanaka","year":"2023","journal-title":"Cancer Med"},{"key":"2026100705504563600_bib45","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/j.ejca.2021.08.048","article-title":"The determinants of very severe immune-related adverse events associated with immune checkpoint inhibitors: a prospective study of the French REISAMIC registry","volume":"158","author":"Ruste","year":"2021","journal-title":"Eur J Cancer"},{"key":"2026100705504563600_bib46","doi-asserted-by":"publisher","first-page":"114075","DOI":"10.1016\/j.ejca.2024.114075","article-title":"Reactions and adverse events induced by T-cell engagers as anti-cancer immunotherapies, a comprehensive review","volume":"205","author":"G\u00e9raud","year":"2024","journal-title":"Eur J Cancer"}],"container-title":["Cancer Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/doi\/10.1158\/2767-9764.CRC-26-0171\/3832334\/crc-26-0171.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/6\/10\/2339\/3836456\/crc-26-0171.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/6\/10\/2339\/3836456\/crc-26-0171.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T09:50:55Z","timestamp":1791366655000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article\/6\/10\/2339\/788767\/Gustave-Roussy-Immune-Score-Validation-in-Patients"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,1]]},"references-count":46,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10,1]]}},"URL":"https:\/\/doi.org\/10.1158\/2767-9764.crc-26-0171","relation":{"has-preprint":[{"id-type":"doi","id":"10.1158\/2767-9764.c.8758792","asserted-by":"object"}],"is-supplemented-by":[{"id-type":"doi","id":"10.1158\/2767-9764.34156096","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.34156087","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.34156099","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.34156111","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.34156102","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.34156105","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.34156090","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.34156093","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.34156108","asserted-by":"object"}]},"ISSN":["2767-9764"],"issn-type":[{"value":"2767-9764","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,1]]}}}